Rheumatology

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, talk about the importance of shared decision-making in the treatment of psoriatic arthritis.

Thought leaders discuss differences in recommendations between guidelines for the management of psoriatic arthritis.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, discuss the common triggers patients with psoriatic arthritis and the importance of stress management.

The American College of Rheumatology releases 2 new guidelines for treating patients with juvenile idiopathic arthritis.

New recommendations were released by ACR and AAHKS regarding perioperative management of antirheumatic medications for patients with rheumatic diseases undergoing these procedures.

Expert John Sergent, MD, goes into detail about myositis and how to differentiate it from other inflammatory diseases.

These prominent leaders in the field of autoimmune disease discuss AHN's Autoimmunity Institute joining forces with the Relapsing Polychondritis Foundation.

Why is Rare Disease Day so important? Hear the answers from some of the most qualified professionals in rare disease fields.

Vibeke Strand, MD, shares that based on her data, secukinumab is an effective option for treating patients with psoriatic arthritis.

The Chair of the ACR COVID-19 Vaccine Clinical Guidance Task Force shares what was learned from the Omicron variant and how the recommendations for rheumatologists has been affected by it.

Chair of the ACR COVID-19 Vaccine Clinical Guidance Task Force, Jeffrey Curtis, discusses the newest vaccine recommendations amid the Omicron variant.

Vibeke Strand explains that secukinumab improves psoriatic arthritis in patients regardless of their treatment history.

Phase 3 of the FUTURE 5 trial further examined the efficacious effect that secukinumab had on patients with psoriatic arthritis.

The fifth update from the American College of Rheumatology supports fourth doses of the vaccine for high-risk rheumatic disease patients.

Less than 5% of patients with IBD treated with azathioprine had white blood count, eGFR, ALT, and neutrophil abnormalities.

The FDA was prompted to require a safety trial comparing tofacitinib with TNF inhibitors in patients with rheumatoid arthritis.

New data show that even though physical therapy may be the more expensive treatment for knee osteoarthritis, it’s more effective than intra-articular glucocorticoid injection.

Contrary to recent research that indicated a higher risk of death associated with escalating doses of allopurinol for chronic kidney disease, investigators announce no association between allopurinol initiation and increased mortality among patients with gout and CKD.

Promising results were announced by UCB after a Phase 3 study evaluated bimekizumab for non-radiographic axial spondyloarthritis and met all endpoints.

Investigators closely examine the differences between neuromuscular changes associated with normal aging and those associated with age-related disorders and how they affect individuals with knee osteoarthritis.

Novartis receives approval for Cosentyx, their biologic treatment for enthesitis-related arthritis and juvenile psoriatic arthritis, in children and adolescents.

The JAK inhibitor therapy was supported by a pair of phase 3 trials showing improved disease control in treated patients.

Guselkumab is the first and only selective interleukin inhibitor therapy in the US that's approved for both moderate-severe plaque psoriasis and active psoriatic arthritis regardless of prior TNFi exposure.

Despite the increasing trend of PRP in knee osteoarthritis, most clinical guidelines do not recommend it due to a lack of evidence on its efficacy.

Continual improvement was shown in patient-reported pain levels when treated with guselkumab compared with placebo.

An interview on new findings suggesting baseline heart failure may be an indicator of increased mortality risk in patients treating arthritis with the DMARD.

Results show that antimetabolites and BCDT medications were frequently represented in the group of vaccinated patients who were hospitalized for COVID-19.

A team from Vanderbilt identified 4 key predictors from a retrospective analysis of cases since 2020.

Interventions for patients with systemic lupus erythematosus (SLE) need to address physician/patient communication to improve health outcomes, according to Dr. Maheswaranathan.